pr-inside.com
Print
Novacta Biosystems Limited - Product Pipeline Review - 2012

Novacta Biosystems Limited - Product Pipeline Review - 2012 - new company profile report published



companiesandmarkets.com
2012-12-04 08:55:57 - Novacta Biosystems Limited - Product Pipeline Review - 2012 - a new company profile report on companiesandmarkets.com

Novacta Biosystems Limited – Product Pipeline Review – 2012 - Global Market Direct´s pharmaceuticals report, "Novacta Biosystems Limited - Product Pipeline Review - 2012" provides data on the Novacta Biosystems Limited´s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data

 

 

and information sourced from our proprietary databases, Novacta Biosystems Limited´s corporate website, SEC filings, investor presentations and featured press releases, both from Novacta Biosystems Limited and industry-specific third party sources, put together by our team.

Scope

- Novacta Biosystems Limited - Brief Novacta Biosystems Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Novacta Biosystems Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Novacta Biosystems Limited with complete description of the product´s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Novacta Biosystems Limited´s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Novacta Biosystems Limited´s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Novacta Biosystems Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Novacta Biosystems Limited´s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Novacta Biosystems Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Novacta Biosystems Limited and identify potential opportunities in those areas.

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Company Profile Reports www.companiesandmarkets.com/Market/All/Company-Profile?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Author:
Mike King
e-mail
Web: http://www.companiesandmarkets.com
Telefon: London: +44 (0) 203 086 8600




Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.